Clinical trials
Completed Phase 1/2 Burkitt Lymphoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 6 |
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fred Hutchinson Cancer Center | 6 |
| Mayo Clinic | 3 |
| Northwestern University | 3 |
| Garden State Cancer Center at the Center for Molecular Medicine and Immunology | 2 |
| National Cancer Institute (NCI) | 2 |
| UNC Lineberger Comprehensive Cancer Center | 2 |
| Acerta Pharma BV | 1 |
| Amgen Research (Munich) GmbH | 1 |
| Asan Medical Center | 1 |
| Atara Biotherapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Burkitt Lymphoma | 42 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 32 |
| Lymphoma, Large B-Cell, Diffuse | 31 |
| Lymphoma, Follicular | 30 |
| Lymphoma, Mantle-Cell | 30 |
| Lymphoma, B-Cell, Marginal Zone | 26 |
| Lymphoma, Large-Cell, Immunoblastic | 26 |
| Lymphoma, Non-Hodgkin | 26 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 25 |
| Lymphoma | 25 |
Trials
Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.